DMG-ACT — From Vision to Clinical Activation

DMG-ACT (Diffuse Midline Glioma – Adaptive Combinatorial Therapy) is a global, multidisciplinary initiative transforming how children with DIPG and DMG are treated. Built on the belief that no single therapy will defeat these heterogeneous and aggressive tumors, DMG-ACT brings together world-leading preclinical and clinical scientists and institutions to rapidly identify, test, and advance the most promising treatment combinations for children battling these cancers.

In 2021, DMG-ACT transitioned from concept to clinical reality. With foundational infrastructure in place, the Pediatric Neuro-Oncology Consortium (PNOC) launched PNOC022, the adaptive platform trial that serves as the clinical backbone of DMG-ACT. Patient enrollment began in November 2021, marking a critical inflection point for the field.

The year 2021 focused on operational readiness: activating sites, aligning international collaborators, and implementing a trial design that allowed therapies to be tested across newly diagnosed, post-radiation, and recurrent DMG populations. ChadTough’s continued support ensured that the trial could move forward efficiently while maintaining rigorous scientific and ethical standards. By the end of 2021, DMG-ACT had become one of the most ambitious collaborative efforts ever undertaken in pediatric brain tumor research.